キメラ抗原受容体(CAR)-T細胞療法市場：研究開発の現状

Report Highlights

The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.

CAR-T細胞療法の世界市場は、2024年の46億ドルから2024年から2029年にかけて40.2%の複合年間成長率（CAGR）で成長し、2029年末までに251億ドルに達すると予測されています。

Summary

CAR T-cell therapy is a novel method for treating hematologic tumors that were previously considered incurable and have been developed by modifying a patient’s T cells to express a chimeric antigen receptor (CAR) unique to a tumor antigen (TA). The foundation of this treatment is the CAR’s ability to attach to antigens, which results in a strong T-cell activation and anti-tumor response. Tisagenlecleucel was the first FDA-licensed CAR T-cell therapy authorized in 2017 for treating acute lymphoblastic leukemia in children and young adults.

CAR-T細胞療法は、これまで治療不可能と考えられていた血液腫瘍を治療する新しい方法であり、患者の T 細胞を改変して腫瘍抗原 (TA) に固有のキメラ抗原受容体 (CAR) を発現させることによって開発されました。この治療の基礎は、CAR が抗原に結合する能力であり、これにより強力な T 細胞活性化と抗腫瘍反応がもたらされます。チサゲンレクロイセルは、小児および若年成人の急性リンパ性白血病の治療薬として 2017 年に承認された、FDA 認可の最初の CAR-T細胞療法です。

CAR T-cell therapy holds a huge potential benefit, due to its being tailored to each patient’s needs. To target and eliminate cancer cells, T cells are extracted from the patient, genetically altered in the lab to produce CARs on their surface and reintroduced into the patient. CAR T-cell-based treatments have attracted much interest in solid tumors because of their remarkable effectiveness in hematological malignancies. There are now six autologous CAR T-cell treatments that have received FDA approval and are used to treat different types of blood cancer in the U.S. CAR T-cell treatments are being studied in 1,439 clinical studies worldwide in addition to these commercially available products.

Report Synopsis

Report Scope

This report incorporates an in-depth analysis of CAR T-cell therapy’s current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players’ profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies’ business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.

このレポートには、2023年を基準年として2024年から2029年までの年平均成長率（CAGR）予測を用いた市場予測やトレンドを含むCAR-T細胞療法の現在の研究開発状況の詳細な分析が組み込まれています。業界構造とその競争環境の概要を提供します。主要な市場プレーヤーのプロファイル、製品提供、財務情報、最近の市場活動が提供されています。このレポートでは、企業のビジネス戦略と競争環境に対するその影響も評価しています。このレポートでは、製品に基づいてCAR T細胞療法市場の詳細を説明しています。CAR-T細胞技術の歴史的発展、CAR-T細胞療法における進行中の臨床的および非臨床的進歩、および規制要件をレビューしています。地域分析には、米国および国際市場が含まれます。

Report Includes

– 14 data tables and 71 additional tables

– Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D

– Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029

– Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region

– Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors

– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses

– Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry

– An analysis of patents, emerging trends and developments in the industry

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

– Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

Market and Technology Background

A Brief History of CAR T-Cell Therapy

FDA Product Approvals

Other CAR T-Cell Therapies

Clinical Applications of CAR T-Cell Therapy

Adoptive Cell Transfer (ACT) Technologies

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Increasing Incidence of Cancer

Growing Investments and Funding in CAR T-Cell Therapy Research

Robust R&D Pipeline

Advances in Genetic Engineering

Market Restraints

Complex Legislative and Regulatory Procedures

Alternative Products from Competitors

Market Opportunities

Growing Significance of Precision Medicine

Expanding Applications for CAR T-Cell Therapy

Market Challenges

Complex Manufacturing and Supply Chain

Reimbursement Challenges for CAR T-Cell Therapy

Chapter 4 Emerging Technologies and Clinical Trials

Introduction

Clinical Trials Being Conducted Globally

Distribution of CAR T-Cell Clinical Trials in China

Chapter 5 Market Segmentation Analysis

Key Takeaways

Segmentation Breakdown

Global Market for CAR T-Cell Therapy, by Product

Yescarta

Kymriah

Tecartus

Abecma

Breyanzi

Carvykti

Global Market for CAR T-Cell Therapy, by Indication

Geographic Breakdown

Global Market for CAR T-Cell Therapy, by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 6 Patent Review and New Developments

Introduction

Anticipated Increase in Patent Litigation on Customized Patient Treatments

Company-specific Intellectual Property and Patent Information

Amgen

Avacta Life Sciences Ltd.

Bluebird Bio

Celgene Corp.

Cellectis

Celyad SA

Editas Medicine Inc.

Eureka Therapeutics Inc.

iCell Gene Therapeutics

Juno Therapeutics Inc. (A Celgene Co.)

Noile-Immune Biotech

Novartis AG

Chapter 7 Competitive Intelligence

Ranking of Leading Players

Strategic Considerations

Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective

Introduction to ESG

Role of ESG in the Pharma Industry

ESG Performance Analysis

Environmental

Social

Governance

ESG Risk Ratings

Conclusion

Chapter 9 Appendix

Methodology

Abbreviations

References

Company Profiles

ABBVIE INC.

ALLOGENE THERAPEUTICS

AMGEN INC.

ASTRAZENECA

BLUEBIRD BIO INC.

BRISTOL-MYERS SQUIBB CO.

CELLECTIS S.A.

EUREKA THERAPEUTICS INC.

GILEAD SCIENCES INC.

ICELL GENE THERAPEUTICS INC.

JOHNSON & JOHNSON SERVICES INC.

LES LABORATOIRES SERVIER

NOVARTIS AG

PFIZER INC.

PROTHERAGEN INC.

List of Tables

Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029

Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017–2022

Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues

Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets

Table 4 : Global Cancer Statistics, 2022

Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023

Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023

Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company

Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.

Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China

Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China

Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China

Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China

Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029

Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029

Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications

Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029

Table 17 : Bluebird Bio: Patents and Patent Applications, 2012–2021

Table 18 : Celgene Corp.: Patents and Patent Applications, 2018–2021

Table 19 : Cellectis: Patents and Patent Applications, 2018–2021

Table 20 : Editas Medicine: Patent Applications, 2015–2021

Table 21 : Eureka Therapeutics: Patent Applications, 2012–2021

Table 22 : iCell Gene Therapeutics: Patent Applications, 2017–2019

Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000–2021

Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017

Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013–2021

Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023

Table 27 : Focus Areas in ESG Metrics

Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*

Table 29 : Abbreviations Used in this Report

Table 30 : AbbVie Inc.: Company Snapshot

Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023

Table 32 : AbbVie Inc.: Product Portfolio

Table 33 : AbbVie Inc.: News/Key Developments, 2023–2024

Table 34 : Allogene Therapeutics: Company Snapshot

Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023

Table 36 : Allogene Therapeutics: Product Portfolio

Table 37 : Allogene Therapeutics: News/Key Developments, 2024

Table 38 : Amgen Inc.: Company Snapshot

Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 40 : Amgen Inc.: Product Portfolio

Table 41 : Amgen Inc.: News/Key Developments, 2024

Table 42 : AstraZeneca: Company Snapshot

Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023

Table 44 : AstraZeneca: Product Portfolio

Table 45 : AstraZeneca: News/Key Developments, 2023–2024

Table 46 : Bluebird Bio Inc.: Company Snapshot

Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023

Table 48 : Bluebird Bio Inc.: Product Portfolio

Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022

Table 50 : Bristol-Myers Squibb Co.: Company Snapshot

Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023

Table 52 : Bristol-Myers Squibb Co.: Product Portfolio

Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023–2024

Table 54 : Cellectis S.A.: Company Snapshot

Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023

Table 56 : Cellectis S.A.: Product Portfolio

Table 57 : Cellectis S.A.: News/Key Developments, 2023–2024

Table 58 : Eureka Therapeutics Inc.: Company Snapshot

Table 59 : Eureka Therapeutics Inc: Product Portfolio

Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023–2024

Table 61 : Gilead Sciences Inc.: Company Snapshot

Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023

Table 63 : Gilead Sciences Inc.: Product Portfolio

Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022–2024

Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot

Table 66 : iCell Gene Therapeutics Inc: Product Portfolio

Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024

Table 68 : Johnson & Johnson Services Inc.: Company Snapshot

Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023

Table 70 : Johnson & Johnson Services Inc.: Product Portfolio

Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022–2024

Table 72 : Les Laboratoires Servier: Company Snapshot

Table 73 : Les Laboratoires Servier: Product Portfolio

Table 74 : Les Laboratoires Servier: News/Key Developments, 2024

Table 75 : Novartis AG: Company Snapshot

Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023

Table 77 : Novartis AG: Product Portfolio

Table 78 : Novartis AG: News/Key Developments, 2021–2024

Table 79 : Pfizer Inc.: Company Snapshot

Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023

Table 81 : Pfizer Inc.: Product Portfolio

Table 82 : Pfizer Inc.: News/Key Developments, 2023

Table 83 : Protheragen Inc.: Company Snapshot

Table 84 : Protheragen Inc.: Product Portfolio

List of Figures

Summary Figure : Global Market for CAR T-Cell Therapy, by Product, 2022–2029

Figure 1 : Historical Development of CAR T-Cell Therapy, 1992–2017

Figure 2 : Snapshot of the Market Dynamics for CAR T-Cell Therapy

Figure 3 : Estimated New Cancer Cases, 2022, 2045 and 2050

Figure 4 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Status, January 2023

Figure 5 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Study Phase, January 2023

Figure 6 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Investigator Type, January 2023

Figure 7 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2021–2024

Figure 8 : Global Market Shares of CAR T-Cell Therapy, by Product, 2024

Figure 9 : Global Market Shares for Yescarta, by Region, 2024

Figure 10 : Global Market Shares for Kymriah, by Region, 2024

Figure 11 : Global Market Shares for Tecartus, by Region, 2024

Figure 12 : Global Market Shares for Abecma, by Region, 2024

Figure 13 : Global Market Shares for Breyanzi, by Region, 2024

Figure 14 : Global Market Shares for Carvykti, by Region, 2024

Figure 15 : Global Market Shares of CAR T-Cells Therapy, by Indication, 2024

Figure 16 : Global Market Shares of CAR T-Cell Therapy, by Region, 2024

Figure 17 : Strategic Considerations

Figure 18 : How a Strong ESG Proposition Benefits Businesses

Figure 19 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023

Figure 20 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023

Figure 21 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023

Figure 22 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023

Figure 23 : AstraZeneca: Revenue Share, by Business Unit, FY 2023

Figure 24 : AstraZeneca: Revenue Share, by Region/Country, FY 2023

Figure 25 : Bristol Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023

Figure 26 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023

Figure 27 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023

Figure 28 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023

Figure 29 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023

Figure 30 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023

Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023

Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023

Figure 33 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023

Figure 34 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• がん免疫療法の技術と世界市場 2025-04-17
• 再生可能エネルギーの技術と世界市場 2025-04-17
• 木材・プラスチック複合材の技術と世界市場 2025-04-17
• 先端材料の調査レビュー　2024年 2025-04-16
• コールドチェーンの地域別市場分析：中東＆北アフリカ 2025-04-16

BCC Research  出版レポート一覧